1. Home
  2. ACAD vs BANF Comparison

ACAD vs BANF Comparison

Compare ACAD & BANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.89

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo BancFirst Corporation

BANF

BancFirst Corporation

HOLD

Current Price

$112.20

Market Cap

3.9B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACAD
BANF
Founded
1993
1984
Country
United States
United States
Employees
N/A
2135
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.9B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
ACAD
BANF
Price
$21.89
$112.20
Analyst Decision
Buy
Hold
Analyst Count
22
2
Target Price
$30.55
$124.00
AVG Volume (30 Days)
1.3M
93.5K
Earning Date
05-06-2026
04-16-2026
Dividend Yield
N/A
1.76%
EPS Growth
69.12
N/A
EPS
2.30
N/A
Revenue
$726,437,000.00
N/A
Revenue This Year
$18.80
$6.10
Revenue Next Year
$11.70
$3.92
P/E Ratio
$9.80
$16.38
Revenue Growth
40.45
N/A
52 Week Low
$14.45
$101.48
52 Week High
$28.35
$138.15

Technical Indicators

Market Signals
Indicator
ACAD
BANF
Relative Strength Index (RSI) 48.06 53.61
Support Level $21.51 $111.45
Resistance Level $22.03 $115.71
Average True Range (ATR) 0.61 3.17
MACD 0.05 -0.27
Stochastic Oscillator 44.95 32.15

Price Performance

Historical Comparison
ACAD
BANF

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About BANF BancFirst Corporation

BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.

Share on Social Networks: